SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron is trending amidst an "unprecedented" memory shortage, fueled by surging AI demand for High-Bandwidth Memory (HBM) that experts project will persist into 2027. The community is highly optimistic, highlighting Micron's unique position as the sole U.S. HBM producer, its relatively low valuation, and recent analyst upgrades. This strong bullish sentiment is reinforced by news of significant manufacturing expansions and a substantial insider share purchase.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is currently a major talking point due to its imminent earnings report and ongoing speculation regarding its potential acquisition of Warner Bros. Discovery assets. The community is sharply divided, debating the strategic implications of the WBD deal and reacting to news of a notable bond purchase by a prominent political figure. Traders are anticipating significant volatility, with many viewing the stock as oversold and poised for a substantial move.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio (IBRX) is trending intensely following Saudi Arabia's groundbreaking approval of its Anktiva treatment for lung cancer, marking the first global nod for this non-chemo combination, alongside significant progress in its AI-driven NK cell manufacturing. This development, amplified by Dr. Patrick Soon-Shiong's direct public engagement, is fueling widespread community excitement about a potential paradigm shift in oncology and fervent speculation regarding a short squeeze amidst high market interest. Investors and patients alike are discussing the implications of international regulatory confidence and the company's efforts to revolutionize cancer treatment accessibility and cost, putting immense pressure on traditional pharmaceutical and regulatory landscapes.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

Applovin is currently trending due to a sharp price drop and heightened volatility, fueled by recent critical reports and ongoing speculation of market manipulation. Despite the downturn, community discussions highlight conviction in its robust AI-powered ad platform and anticipate a rebound, particularly with upcoming earnings expected to showcase strong fundamentals.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is actively trending due to reports of China blocking shipments of its H200 AI chips, coupled with broader market uncertainty from escalating international trade tensions. While some investors anticipate market turbulence, a strong bullish contingent emphasizes NVIDIA's entrenched AI leadership and robust demand for its next-generation Blackwell and Rubin platforms, viewing current dips as prime buying opportunities.

Venus Concept, Inc. is a global medical technology company, which engages in the business of developing, commercializing, and selling minimally invasive and non-invasive medical aesthetic and hair restoration technologies. It operates under the United States and International geographical segments. The company was founded on November 22, 2002 and is headquartered in Toronto, Canada.

Venus Concept Inc

Venus Concept Inc. (VERO) is trending following the disclosure that a single institutional shareholder now controls 91% of the company's shares, creating an extremely tight public float. This has spurred a heated debate among investors, with many anticipating an unprecedented short squeeze and significant price appreciation due to the limited tradable shares. Conversely, a vocal group warns of a potential pump-and-dump, highlighting the company's underlying fundamentals and the risk of delisting at a low valuation.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. is trending as investors anticipate an upcoming business update call, which follows a major joint venture with a Saudi industrial conglomerate securing 100% offtake for its Greenland rare earth production. The community is buzzing with discussion around Greenland's strategic importance for critical minerals, intensified by geopolitical developments highlighting the need for secure supply chains. This confluence of news positions CRML as a central focus for those seeking exposure to the crucial rare earths sector.

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is actively discussed amidst renewed concerns over potential US tariffs on European economies related to Greenland, which has prompted caution in European markets and the bond sector. This geopolitical tension has sharply divided the community, with many anticipating a significant market pullback, while a strong counter-narrative expects a swift "buy the dip" recovery based on historical resilience to similar events.

Smith & Wesson Brands, Inc. is a holding company, which engages in the manufacture, design, and provision of firearms. Its portfolio includes handguns, long guns, handcuffs, suppressor, and other firearm-related products. The firm's brands are Smith & Wesson, M&P, Thompson/Center Arms, and Gemtech. The company was founded by Horace Smith and Daniel Baird Wesson in 1852 and is headquartered in Maryville, TN.

Smith & Wesson Brands Inc

Smith & Wesson Brands is trending due to a mix of recent disappointing earnings and significant regulatory developments. While the company missed profit and revenue estimates, sparking community concerns, there's a strong undercurrent of optimism driven by proposed Justice Department changes to ease gun regulations and the rescission of strict firearm export controls. Investors are actively discussing the potential for increased firearm demand amid broader themes of civil unrest and political uncertainty, positioning the stock as a long-term play despite short-term headwinds.

United States Commodity Funds LLC - United States Natural Gas Fund

United States Natural Gas Fund, LP

The United States Natural Gas Fund (UNG) is trending due to forecasts predicting an intense cold snap across large parts of the US, which is expected to significantly boost heating demand. Community sentiment is largely divided between those anticipating a major short squeeze and a sustained rally, possibly fueled by growing energy needs for AI data centers, and those remaining wary of natural gas's notorious volatility and strong production levels that could temper further gains.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The trial compares Bacillus Calmette-Guérin (BCG) therapy alone with BCG combined with ANKTIVA.</li><li>Preliminary analysis showed that ANKTIVA plus BCG significantly extended the duration of complete response in BCG-naïve cancer patients.</li><li>ImmunityBio plans to submit a biologics license application to the FDA by the end of 2026.</li></ul>ImmunityBio, Inc. (IBRX) shares jumped 24% in premarket trading on Friday after the company reported a faster than expected enrollment for its QUILT-2.005 bladder cancer drug trial.The company said that enrollment has surpassed internal expectations and is now more than 85% complete, with full enrollment of the planned study population expected by the second quarter of 2026.&nbsp;Based on current progress, ImmunityBio plans to submit a biologics license application to the U.S. Food and Drug Administration (FDA) by the end of 2026.“We look forward to the final accrual of this important registrational randomized trial in patients with BCG-naïve non-muscle-invasive bladder cancer, which represents a substantial proportion of newly diagnosed bladder cancer cases. The interim analysis is encouraging and consistent with findings in the approved BCG-unresponsive setting, where the duration of complete response has exceeded 47 months,” said Patrick Soon-Shiong, M.D., Founder, Executive Chairman, and Global Chief Medical and Scientific Officer of ImmunityBio.Based on current progress, ImmunityBio plans to submit a biologics license application to the FDA by the end of 2026.<h2 class="st-heading-2">What Is The Trial About?</h2>The QUILT-2.005 is a clinical trial for Bacillus Calmette-Guérin (BCG) naïve non-muscle-invasive bladder cancer (NMIBC) that compares standard BCG therapy alone versus BCG combined with ANKTIVA, an Interleukin-15 (IL-15) receptor agonist. IL-15 is an immune system protein that helps develop and activate key cells that work to destroy cancer cells.In 2023, the FDA requested an interim analysis of the randomized trial to evaluate the added benefit of ANKTIVA when combined with BCG, focusing on complete response rates and the durability of response versus BCG alone.The analysis showed that ANKTIVA plus BCG significantly extended the duration of complete response in BCG-naïve NMIBC patients. At six months, 85% of patients receiving the combination maintained a complete response, compared with 57% in the BCG-only group. At nine months, response rates were 84% with combination therapy versus 52% with BCG alone.<h2 class="st-heading-2">How Did Retail React?</h2>Retail sentiment for <a href="https://stocktwits.com/symbol/IBRX">IBRX</a> on Stocktwits remained in the ‘extremely bullish’ zone over the past 24 hours, amid ‘extremely high’ message volumes.<img src="https://news.stocktwits-cdn.com/IBRX_jpg_3d2f27a76b.webp" alt="IBRX.jpg">One user was bullish about the company’s potential.<stembedurl>https://stocktwits.com/Amit18/message/642024906</stembedurl>Another user saw the stock as a long-term runner.<stembedurl>https://stocktwits.com/LeftyT/message/642025351</stembedurl>Over the past year, the stock has gained more than 60%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/rklb-stock-set-for-all-time-high-morgan-stanley-boost/cmUlAaBR4B7">RKLB Stock Is On Track For Record Open – Here’s What’s Driving The Rally</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, an ImmunityBio company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Why IBRX Stock Is One Of The Biggest Pre-Market Movers Today 

The company said that enrollment for its randomized registrational QUILT-2.005 trial has surpassed internal expectations and is now more than 85% complete.

 IBRX Stock Rallies As Its Bladder Cancer Study Nears Full Enrollment 

Equity

<ul class="summary-bullets"><li>Galaxy said that ERCOT approval effectively doubles the data center’s capacity, taking it to over 1.6 gigawatts.</li><li>Construction is underway under the company’s long-term lease with CoreWeave, with initial power delivery expected in early 2026.</li><li>The company also announced the completion of its first-ever tokenized collateralized loan obligation, Galaxy CLO 2025-1, on the Avalanche blockchain platform. &nbsp;</li></ul>Galaxy Digital Inc. (GLXY) stock jumped 10% on Thursday as investors reacted to two major developments, including an approval for an additional 830 megawatts (MW) of power at its Helios data center campus in Texas, positioning the company for significant expansion in AI and high-performance computing infrastructure.The stock is on track to close in the green for a fourth successive session. <a href="https://stocktwits.com/symbol/GLXY">GLXY</a> was also among the top trending tickers on Stocktwits at the time of writing.<h2 class="st-heading-2">ERCOT Approval</h2>Galaxy said that the approval by the Electric Reliability Council of Texas (ERCOT) effectively doubles the data center’s previously approved power capacity, taking it to over 1.6 gigawatts (GW).Galaxy signed a service agreement with AEP Texas for the new capacity, with Wind Energy Transmission Texas (WETT) serving as the transmission interconnection provider.The company said that construction is underway under the company’s long-term lease with CoreWeave, with initial power delivery expected in early 2026. Galaxy added that it is exploring additional power and land opportunities in Texas and beyond.<h2 class="st-heading-2">Tokenized CLO Execution</h2>In a separate release, the company announced the completion of its first-ever tokenized collateralized loan obligation (CLO), Galaxy CLO 2025-1, on the Avalanche blockchain platform.The CLO supports a flexible credit line for Arch Lending, a crypto-backed consumer loan platform. It gradually buys loans backed by Bitcoin, Ethereum, and other crypto assets, and can grow up to $200 million as more loans are issued.“By uniting our strengths in debt capital markets, blockchain technology, and asset management, we're opening a new avenue for institutional engagement in credit markets—one that benefits from greater efficiency, transparency, and expanded collateral flexibility through onchain execution,” said Chris Ferraro, President and Chief Investment Officer at Galaxy.<h2 class="st-heading-2">Retail Reaction</h2>Retail sentiment on Stocktwits trended in the ‘extremely bullish’ territory at the time of writing, while message volumes were at ‘extremely high’ levels.<img src="https://news.stocktwits-cdn.com/GLXY_jpg_8447717cc7.webp" alt="GLXY.jpg">One user was bullish about the ERCOT approval, stating it gives Galaxy a major advantage in AI and HPC infrastructure.<stembedurl>https://stocktwits.com/KavaStocks/message/641919100</stembedurl>Another user saw the power expansion news as “massive” and expects the stock to climb to $50, a near 40% upside to the current price of $30.4.<stembedurl>https://stocktwits.com/justAuselessGhOsT/message/641900630</stembedurl>Over the past year, GLXY stock has gained over 60%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/why-did-sphl-stock-surge-over-270-oercent-today/cmU181cR4Jc">This Microcap Stock Surged Over 270% Today – What Triggered The Rally?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

 In this photo illustration, the Galaxy Digital logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

GLXY Stock Rallied 10% Today – What Are The Two Factors At Play?

The company secured approval for an additional 830 megawatts of power at its Helios data center campus in Texas and completed its first-ever tokenized collateralized loan obligation.

<ul class="summary-bullets"><li>ImmunityBio plans to establish a regional office in Saudi Arabia to support its expansion across the Middle East and North Africa.</li><li>The company will also partner with regional pharmaceutical firm BioPharma Cigalah.</li><li>Enrolment for the QUILT-2.005 study evaluating ANKTIVA with BCG in earlier-stage bladder cancer is expected to be completed by the second quarter.</li></ul>ImmunityBio, Inc. (IBRX) drew retail attention on Wednesday as the stock jumped 8% after the Saudi Food and Drug Authority approved ANKTIVA in combination with the BCG (Bacillus Calmette-Guérin) vaccine to treat adults with BCG-unresponsive non-muscle invasive bladder cancer.The approval marks a major regulatory milestone, adding to existing authorizations in the United States and the United Kingdom, as well as conditional approval in the European Union.“We are pleased to bring ANKTIVA to Saudi patients with NMIBC, who otherwise have no viable options but life-altering surgery,” said Rich Adcock, Chief Executive Officer, ImmunityBio.<h2 class="st-heading-2">ImmunityBio’s Expansion Plans</h2>ImmunityBio plans to establish a regional office in Saudi Arabia to support its expansion across the Middle East and North Africa. The company will also partner with regional pharmaceutical firm BioPharma Cigalah. Management cited the rising incidence of bladder and other cancers in the region as a key driver behind the strategy.ANKTIVA is an Interleukin-15 (IL-15) receptor agonist. IL-15 is an immune system protein that helps develop and activate key cells that work to destroy cancer cells.<h2 class="st-heading-2">ANKTIVA Developments</h2>Beyond bladder cancer, ANKTIVA is also drawing attention for its broader oncology potential. <a href="https://stocktwits.com/news-articles/markets/equity/why-did-ibrx-stock-surge-today/cmUXXCjR4Ig">Recent clinical data</a> from the QUILT-2.023 and QUILT-3.055 trials in non-small cell lung cancer (NSCLC) showed improved immune recovery and extended survival when ANKTIVA was combined with checkpoint inhibitors.Responding patients achieved a median survival of up to 21.1 months, significantly outperforming traditional chemotherapy outcomes.Meanwhile, enrolment for the company’s QUILT-2.005 study evaluating ANKTIVA with BCG in earlier-stage bladder cancer is expected to be completed by the second quarter (Q2) of 2026 and a potential biologics license application (BLA) by the end of the year.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits around ImmunityBio remained in the ‘extremely bullish’ zone, amid ‘extremely high’ message volumes.<img src="https://news.stocktwits-cdn.com/IBRX_jpg_1a3db9b5f3.webp" alt="IBRX.jpg">One user speculated that the approval could double the product revenue for the company.<stembedurl>https://stocktwits.com/Bc3345/message/641787673</stembedurl>One user sees the stock climb to $5 in the short term and $15-25 in the medium term.<stembedurl>https://stocktwits.com/AshvsEvilDead/message/64178170</stembedurl><a href="https://stocktwits.com/AshvsEvilDead/message/641781706">6</a>Over the past year, <a href="https://stocktwits.com/symbol/IBRX">IBRX shares</a> have risen around 21%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/why-clsk-stock-rising-premarket-texas-data-centre-deal/cmULgA7R4e0">CLSK Stock Receives Premarket Boost On Texas Data Center Deal</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

IBRX Stock Finds Retail Cheer After Company’s Immunotherapy For Bladder Cancer Gets Saudi FDA Approval

The approval in Saudi Arabia follows authorizations in the U.S. and the U.K., as well as a conditional approval in the European Union.

<ul class="summary-bullets"><li>The company said that responding patients lived longer overall, with a median survival of 16.2 months.</li><li>The data come from two clinical trials, evaluating 151 patients across first-line and later-line treatment settings.</li><li>ImmunityBio is now advancing its Phase 3 trial, it said.</li></ul>ImmunityBio Inc. (IBRX) stock caught retail attention on Tuesday after the company reported positive clinical results showing its immunotherapy ANKTIVA significantly boosts immune function and improves survival in non-small cell lung cancer (NSCLC) patients when combined with checkpoint inhibitors.The data come from two clinical trials, QUILT-2.023 and QUILT-3.055, evaluating 151 patients across first-line and later-line treatment settings.<a href="https://stocktwits.com/symbol/IBRX">IBRX shares</a> were up 12.4% at the time of writing. Retail chatter increased to ‘high’ on Stocktwits while sentiment shifted to ‘extremely bullish’ from ‘bullish’ a day earlier.<img src="https://news.stocktwits-cdn.com/IBRX_jpg_72f59b2252.webp" alt="IBRX.jpg">One bullish user expects the U.S. Food and Drug Agency (FDA) to approve ANKTIVA for NSCLC and expand access broadly.<stembedurl>https://stocktwits.com/svertical1/message/641645369</stembedurl>Another user sees the benefits of a non-chemotherapy treatment.<stembedurl>https://stocktwits.com/Armymike1981/message/641633526</stembedurl><h2 class="st-heading-2">Outcome Of The Trials</h2>In the first-line QUILT-2.023 study, patients receiving ANKTIVA plus a checkpoint inhibitor showed a statistically significant and sustained increase in absolute lymphocyte count (small white blood cell) compared with checkpoint inhibitor therapy alone. In the second- and later-line QUILT-3.055 study, 77% of patients maintained or restored healthy lymphocyte levels, showing ANKTIVA’s role as a lymphocyte-stimulating agent.The company said that responding patients lived longer overall, with a median survival of 16.2 months, while those with stronger immune recovery had a median survival of 21.1 months, far exceeding historical results with standard chemotherapy.ImmunityBio is now advancing its Phase 3 trial, comparing ANKTIVA plus checkpoint inhibitors to docetaxel in second-line NSCLC, it added.“The results from these studies support a potential paradigm shift toward what we define as Immunotherapy 2.0, which is the coordinated activation of the innate immune system through natural killer cells and the adaptive immune system through T cells to restore immune competence and extend survival,” said Patrick Soon-Shiong, M.D., Founder, Executive Chairman, and Global Chief Scientific and Medical Officer of ImmunityBio.Over the past year, IBRX shares have gained more than 20%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/jpmorgan-q4-revenue-beat-apple-card-reserve-hits-profit/cmUXEfbR44r">JPMorgan Beats Revenue Estimates In Q4 – A Record Quarter For Wealth Unit Offsets Apple Card Drag</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

IBRX Garners Retail Attention On Positive Update In Immunotherapy For Lung Cancer Patients

The company reported positive results with ANKTIVA, which boosted immune function and improved survival in NSCLC when combined with checkpoint inhibitors.

Should Vanguard Small-Cap Growth ETF (VBK) Be on Your Investing Radar?

Enterprise AI software maker C3.ai’s (AI) shares tumbled in Monday’s premarket session as investors reacted to the company’s preliminary results for the first quarter of the fiscal year 2026, reported after the market close on Friday.<a href="https://stocktwits.com/symbol/AI">C3.ai stock</a> tanked nearly 29% at last check in premarket trading. If the premarket losses are sustained in Monday’s regular session, the stock is on track to have its worst day ever, according to Koyfin.The stock was the top trending ticker on Stocktwits early Monday.The Redwood City, California-based company announced preliminary first-quarter revenue of $70.2 million to $70.4 million and adjusted loss from operations of $57.7 million to $57.9 million.The Fiscal.ai-compiled consensus estimates call for revenue of $104.8 million for the quarter. The guidance issued in late May calls for revenue of $100 million to $109 million and adjusted loss from operations of $23.5 million to $33.5 million.The company stated that it would release the completed results and an updated fiscal year 2026 guidance on Sept. 3. In a separate release, the company announced that it has restructured its global sales and services organization, including the appointment of new leadership.Thomas Siebel, Chairman and CEO, said, “The good news is we have completely restructured the sales and services organization, including new and highly experienced leadership across the board to ensure a return to accelerating growth and increased customer success at C3 AI.”“The bad news is that sales results in Q1 were completely unacceptable.”The executive attributed the predicted shortfall to the reorganization with new leadership that had a disruptive effect,&nbsp;as well as his inability to participate actively in the sales process due to a previously disclosed health issue.“That being said, as we enter Q2, we have new leadership in place, a restructuring completed, an extraordinarily large market opportunity, a superlative product offering, and exceptional levels of customer satisfaction, and I am confident the company is positioned to accelerate going forward,” he added.On Stocktwits, retail sentiment toward the stock improved to 'extremely bullish' (85/100) by early Monday, and the message volume perked up to 'extremely high' levels.<figure class="image"><img style="aspect-ratio:622/53;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_11_at_5_51_53_AM_png_a8632eeed6.webp" alt="Screenshot 2025-08-11 at 5.51.53 AM.png" width="622" height="53"><figcaption>AI sentiment and message volume as of 5:50 a.m. ET, Aug. 11 | source: Stocktwits</figcaption></figure>C3.ai stock has fallen over 35% this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-nvidia-amd-shares-are-slipping-premarket-today/chruszjRdIi">Why Nvidia, AMD Shares Are Slipping Premarket Today</a>

In this photo illustration, a C3.ai logo is displayed on the screen of a smartphone. 

Why Is C3.ai Stock Tumbling Premarket Today?

If the premarket losses are sustained in Monday’s regular session, the stock is on track to have its worst day ever, according to Koyfin.

Enterprise AI software company&nbsp;C3.ai Inc. (AI) experienced a 165% increase in Stocktwits user message count over the last 24 hours following the company's launch of a formal process to identify a new CEO on Thursday.Retail sentiment toward the stock improved to ‘neutral’ (50/100) from ‘bearish’ territory the previous day, and the message volume shifted to ‘extremely high’ (80/100) from ‘high’ levels in 24 hours.&nbsp;&nbsp;<figure class="image"><img style="aspect-ratio:969/114;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_25_080839_png_2e264cf724.webp" alt="AI’s Sentiment Meter and Message Volume as of 08.15 a.m. ET on July 25, 2025 | Source: Stocktwits" width="969" height="114"><figcaption>AI’s Sentiment Meter and Message Volume as of 08.15 a.m. ET on July 25, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/AI">C3.ai&nbsp;stock</a> traded over 1% higher in the premarket on Friday.A bullish Stocktwits user expressed confidence in the CEO search process.&nbsp;<stembedurl>https://stocktwits.com/MaxAlpha/message/622398661</stembedurl>Another user also supported the move to infuse “new blood”.<stembedurl>https://stocktwits.com/TheIndustrials/message/622346059</stembedurl>C3.ai’s current CEO and founder, Thomas M. Siebel, is preparing to step back from day-to-day leadership duties due to health challenges.In a statement released by the company, Siebel revealed he has been managing complications from an autoimmune disorder diagnosed earlier this year.&nbsp;The company has engaged a globally recognized executive search firm to oversee the recruitment effort, which will be guided by a special committee comprising C3.ai board members and senior management.Siebel will remain as CEO while the search for his successor is underway. Once a new CEO is appointed, he will transition into the role of Executive Chairman.&nbsp;“For C3 AI to reach its full potential—which I believe is spectacular—the board and I have initiated a search for a new CEO who can take the company to the next level of growth and success,” said Siebel.In the fourth quarter (Q4), the company’s revenue increased 26% year-over-year to $108.7 million, surpassing the analysts’ consensus estimate of $107.7 million, according to Fiscal AI data.C3 offers a suite of solutions, including the C3 Agentic AI Platform, an all-in-one system for building and managing enterprise AI tools.&nbsp;C3.ai stock has lost over 24% year-to-date and over 3% in the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/why-treasure-global-paramount-ast-space-mobile-stocks-are-blowing-up-on-stocktwits/chobbYxR5vy">AI, Mergers, Moonshots: Why Treasure Global, Paramount, AST SpaceMobile Stocks Are Blowing Up On Stocktwits</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration a C3.ai logo is displayed on a smartphone with Artificial Intelligence symbol in the background. 

C3.ai Sees Massive Jump In Retail Chatter As CEO Search Begins

Thomas M. Siebel, the founder and current CEO of C3.ai, is planning to step down, citing health issues.

Deckers Outdoor (DECK) shares rallied 12% in extended trading on Thursday, following the shoemaker's strong first-quarter fiscal 2026 results.Revenue at Deckers, which sells Hoka running shoes and UGG boots, rose 17% to $964.5 million, beating analysts' estimate of $900.4 million. Net income rose to $0.93 per share, handily surpassing the expectation of $0.63.The strong performance points to a nascent rebound after several disappointing quarters that raised concerns about the waning appeal of its Hoka line.<a href="https://stocktwits.com/symbol/DECK">Deckers shares</a> had lost half their value in the first half of 2025, the&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/deckers-is-worst-s-and-p-500-loser-in-h1-as-hoka-shoes-lose-their-kick/chFWPrGRRFN">steepest drop among consumer stocks</a>. In May, the company flagged $150 million in added costs from U.S. tariffs for FY26.A standout item in Deckers' latest results was the company's international expansion. International sales soared 50%, inching closer to its domestic revenue, which fell 3%.On Stocktwits, the retail sentiment shifted from 'bullish' to 'extremely bullish' (93/100).&nbsp;&nbsp;<figure class="image"><img style="aspect-ratio:1400/176;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_25_at_8_18_36_AM_png_4a292b94c3.webp" alt="Screenshot 2025-07-25 at 8.18.36 AM.png" width="1400" height="176"><figcaption>DECK sentiment and message volume as of July 24 | Source: Stocktwits</figcaption></figure>"$DECK shorts getting a little too comfortable, this is at years lows, and the proof in international expansion is just what is needed to catch up to $NKE and prove it has a strong moat," a user said.<stembedurl>https://stocktwits.com/stocksrream/message/622380901</stembedurl>"HOKA and UGG outperformed our first quarter expectations," CEO Stefano Caroti said."Though uncertainty remains elevated in the global trade environment, our confidence in our brands has not changed, and the long-term opportunities ahead are significant."Hoka sales climbed 20%, while Ugg sales rose 19%, above Wall Street's expectations on both counts. Wholesale revenue jumped 27% while direct-to-consumer sales advanced less than 1%.For the&nbsp;current quarter, the company&nbsp;predicts revenue to be&nbsp;between $1.38 billion&nbsp;and $1.42 billion,&nbsp;with the midpoint aligning&nbsp;with current estimates. Earnings per share are anticipated to be $1.50 to $1.55, compared with Wall Street's $1.51.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Hoka shoes are displayed on a shelf at an REI store on May 23, 2025 in Corte Madera, California. (Photo by Justin Sullivan/Getty Images)

Deckers Stock Rallies On Strong Q1, Driven By International Sales Bump: Retail Turns Very Optimistic

Results indicate an early rebound after several disappointing quarters; DECK was the worst-performing consumer stock in the first half of 2025, losing approximately 50% of its value.

VBK
Vanguard Small Cap Growth ETF

Feed

News

Sentiment

Fundamentals

Info

Latest VBK News

VBKVanguard Small Cap Growth ETF